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Abstract
Reliable in vitro models to assess developmental toxicity of drugs and chemicals would lead to improvement in fetal safety 
and a reduced cost of drug development. The validated embryonic stem cell test (EST) uses cardiac differentiation of mouse 
embryonic stem cells (mESCs) to predict in vivo developmental toxicity, but does not take into account the stage-specific 
patterning of progenitor populations into anterior (ventricular) and posterior (atrial) compartments. In this study, we gener-
ated a novel dual reporter mESC line with fluorescent reporters under the control of anterior and posterior cardiac promoters. 
Reporter expression was observed in nascent compartments in transgenic mouse embryos, and mESCs were used to develop 
differentiation assays in which chemical modulators of Wnt (XAV939: 3, 10 µM), retinoic acid (all-trans retinoic acid: 0.1, 
1, 10 µM; 9-cis retinoic acid: 0.1, 1, 10 µM; bexarotene 0.1, 1, 10 µM), and Tgf-β (SB431542: 3, 10 µM) pathways were 
tested for stage- and dose-dependent effects on in vitro anterior–posterior patterning. Our results suggest that with further 
development, the inclusion of anterior–posterior reporter expression could be part of a battery of high-throughput tests used 
to identify and characterize teratogens.
Keywords Teratogen · Cardiogenesis · Atrial cardiomyocyte · Ventricular cardiomyocyte · Stem cells · Anterior–posterior 
patterning · 3R · Developmental toxicity · Embryotoxicity
Introduction
Congenital heart diseases (CHDs) are the most common 
birth defects, with a prevalence in Western Europe of 8.3 
cases per 1000 births (0.83%) (Moons et al. 2009). Among 
the risk factors for heart malformation are genetic predispo-
sition, maternal health, and exposure to teratogens (Dono-
frio et al. 2014). These include drugs commonly taken by 
women of reproductive age, such as anticonvulsants, lithium, 
ACE inhibitors, and retinoids (Donofrio et al. 2014). After 
the retinoid isotretinoin was approved as an acne treat-
ment in the early 1980s, it was taken by 120,000 women 
of childbearing age, and induced spontaneous abortions or 
birth defects in 83% of pregnancies (Stern et al. 1984). In 
line with these potentially severe outcomes, developmen-
tal toxicity studies in pregnant mice and rats are currently 
mandated before approval of novel drugs (DeSesso 2017). 
However, these in vivo tests are low throughput, difficult 
to stage, require specialized expertise for determination of 
adverse effects, and rely on costly animal models (DeSesso 
2017). In Europe alone, the number of animals used for toxi-
cological risk assessment is 1 million per year, and this will 
increase with new testing of industrial chemicals (Kugler 
et al. 2016a, b). The development of robust, high-throughput 
in vitro tests for developmental toxicity is thus an important 
step in the reduction of both industrial expenditure and the 
use of laboratory animals as mandated by 3R principles of 
animal experiments (reduce, refine, replace) (Beekhuijzen 
2017; Russell and Burch 1959).
For in vitro developmental toxicity tests to be reliable, 
multiple mechanisms of drug-induced developmental per-
turbation should be taken into account. These are thought 
to include folate antagonism, neural crest (progenitor) cell 
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disruption, endocrine disruption, oxidative stress, vascu-
lar disruption, and specific receptor- or enzyme-mediated 
effects (van Gelder et al. 2010). These mechanisms are 
not mutually exclusive, as in the case of progenitor cell 
perturbation via binding of toxic compounds to specific 
receptors (van Gelder et al. 2010). Additionally, neural 
crest cell disruption might be expanded to include dis-
ruption of the diverse progenitor populations which give 
rise to the fully formed heart (Jain and Epstein 2018). 
Cell-based assays intended to detect developmental toxic-
ity should thus include cells similar to those encountered 
during embryogenesis, such as undifferentiated progeni-
tors derived from pluripotent stem cells. The validated 
embryonic stem cell test (EST) is an in vitro assay which 
involves compound testing in mouse embryonic stem cells 
(mESCs), immortalized fibroblasts (3T3 cells), and the 
cardiac differentiation of mESCs (Seiler and Spielmann 
2011). The cardiac differentiation protocol used in the EST 
might be improved by considering the diverse progenitor 
populations underlying embryogenesis, the heterogeneous 
cell types composing the fully developed heart, the tempo-
ral and spatial control of cell signaling, and cell-specific 
molecular markers underlying the differentiation process.
Recent studies have shown the tight temporal control of 
signaling pathways during cardiomyocyte differentiation. 
Increased canonical Wnt and bone morphogenetic protein 
(Bmp) signaling promotes the mesodermal specification 
of ESCs, whereas inhibition of these pathways underlies 
the differentiation of progenitor cells to cardiomyocytes 
(Kattman et al. 2011; Kwon et al. 2007; Lian et al. 2012). 
Additionally, there is significant spatial variation in deploy-
ment of signaling pathways which governs the patterning 
of the heart into anterior (ventricular) and posterior (atrial) 
compartments and is predominantly controlled by time- and 
dose-dependent retinoic acid signaling in the developing 
posterior compartment (Ryckebusch et al. 2008; Xavier-Neto 
et al. 1999). However, retinoic acid signaling has also been 
shown to govern heart size via the negative regulation of 
cardiac progenitors (Keegan et al. 2005). Thus, anterior–pos-
terior patterning of organs is a complex process which itself 
encompasses multiple, stage-specific molecular programs.
Though it is not feasible to have an in vitro model which 
incorporates all aspects of development, testing for the per-
turbation of multiple, related lineages simultaneously might 
allow for improved detection of adverse events. Further opti-
mization of protocols to include multiple, short compound 
treatment windows more closely following developmental 
stages and capable of detecting multiple lineages simultane-
ously will provide information on perinatal safety windows 
and mechanisms of developmental toxicity. This is espe-
cially important when attempting to use in vitro models to 
predict effects in clinical settings, as both the stage of preg-
nancy and dosage of exposure to toxic compounds affect the 
likelihood of inducing malformations (Bérard et al. 2007; 
Cooper et al. 2006; Diav-Citrin et al. 2008).
We here describe steps toward improving the existing 
EST using reporter lines for developmental markers of ante-
rior–posterior patterning of the heart. To confirm suitability 
of markers for genetic modification, gene expression profiles 
were generated of embryonic atria and ventricles using a 
selection of markers of atrial cardiomyocytes, ventricular 
cardiomyocytes, cardiac progenitors, nonmyocyte (stromal 
cells), and signaling pathways. Genome editing was used 
to generate a novel dual reporter mESC line for detecting 
anterior and posterior cardiac lineages simultaneously, and 
gene expression analyses of differentiating reporter mESCs 
informed assay development. Chimeric embryos generated 
from these mESCs displayed fluorescent expression in rel-
evant cardiac tissues, and the selected compounds were then 
tested in the spontaneous differentiation of reporter mESCs. 
Finally, a serum-free embryoid body (EB) differentiation 
protocol was conducted in a scalable suspension format, 
allowing the high-throughput testing of differentiation mod-
ulators in cells of a defined mesodermal population. Our 
results give insight into cardiac development and provide 
a basis for further improvements to in vitro toxicological 
assessment of teratogens.
Materials and methods
qRT‑PCR analysis of embryonic atria and ventricles
Embryonic day 10.5 (E10.5) embryonic hearts were removed 
from wild-type pregnant mice (C57BL/6JOlaHsd). Atria and 
ventricles were collected into TRIzol reagent (ThermoFisher 
Scientific), and RNA was extracted according to the manu-
facturer’s instructions. RNA purity was improved using the 
RNeasy MinElute Cleanup kit combined with DNase treat-
ment (Qiagen), and RNA quality was determined via both 
Qubit (ThermoFisher Scientific) and Bioanalyzer (Agilent). 
qRT-PCR reactions were performed using the Fluidigm Bio-
mark HD and Taqman gene expression assays (Supplemen-
tary Table 1). A general list of abbreviations is shown in 
Table 1. Values were normalized to a reference gene (Actb). 
Each biological replicate consisted of four embryos. Sam-
ples from spontaneous differentiation of reporter mESCs 
were similarly processed.
TALEN design, assembly, and validation
A Tal effector nuclease (TALEN) pair targeting the Myl2 
locus was designed using TAL effector-nucleotide targeter 
(Doyle et al. 2012). TALEN-encoding plasmids were assem-
bled using Golden Gate Cloning as described (Cermak et al. 
2011). Plasmids for Golden Gate Cloning were obtained 
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from Addgene. The TAL1 repeat variable diresidue (RVD) 
sequence was ‘NI NN NI NI NN NN HD NN NN NN NI NN 
HD NG HD HD NI’ and the TAL 2 RVD sequence was ‘NN 
NN NI NG HD NG NN NN NN NG HD NG NN HD NG’. 
This TALEN pair recognizes the genomic target sequence 
5′- AGA AGG CGG GAG CTC CAA CGT GTT CTC CAT GTT 
TGA GCA GAC CCA GAT CC-3′ within the Myl2 exon.
Generation of ventricle‑specific targeting vector
The Myl2 targeting vector consisted of a promoterless 
eGFP-bGH-PGK-Puro cassette flanked by 5′ and 3′ homol-
ogy arms. A large fragment encompassing the total homol-
ogous region was amplified from E14 wild-type mESC 
genomic DNA by PCR using 5′-AAC CCC CTC CCA AGC 
CAA GCA-3′ and 5′-ATT CCC CCA AGG GCC AGG TGA-
3′. The 5′ homology arm was amplified from this ampli-
con by PCR using 5′-TGG CGG CCG CTC TAG CCC TCC 
CAA GCC AAG CAC CC-3′ and 5′-GCT CAC CAT GCT 
AGC CAC GTT GGA GCT CCC GCC TTC -3′, whereas 
the 3′ homology arm was amplified from the homologous 
template by PCR using 5′ GCT CTA TGG AGG CCT TCC 
ATG TTT GAG CAG ACC CAGA -3′ and 5′-ATC CAC 
TAG TTC TAG ATT CCC CCA AGG GCC AGG TG-3′. The 
eGFP-bGH-PGK-Puro cassette was constructed by first 
excising eGFP from PITX3-eGFP-PGK-Puro using EcoRI 
and XhoI restriction enzymes, and subcloning this frag-
ment into the pCDNA3.1(−) expression vector upstream 
of the bGH polyA sequence. This eGFP-bGH cassette was 
amplified by PCR using 5′-GCT AGC ATG GTG AGC AAG 
GGCG-3′ and 5′-AGG CCT CCA TAG AGC CCA CCG CAT 
CCC -3′. Primer regions not in bold were added to facili-
tate HD fusion cloning. The 5′ homology arm, eGFP-bGH-
PGK-Puro cassette, and 3′ homology arm were cloned into 
XbaI digested pBluescript II KS( +) using the HD fusion 
cloning kit (Clontech). A PGK-Puro fragment amplified 
by 5′-TGG GCT CTA TGG AGG TCC GAT CAT ATT CAA 
TAA CCC TTA AT-3′ and 5′-CTC AAA CAT GGA AGG 
GGC GCG CCT AGT GAA CCT CT-3′ was ligated into a 
StuI restriction site in the resulting vector to generate the 
final Myl2-eGFP-PGK-Puro donor construct. The plasmid 
was sequenced to ensure fidelity.
Table 1  Abbreviations used in the current study
Abbreviation Full name Abbreviation Full name
9CRA 9-cis retinoic acid Kcne1 Potassium voltage-gated channel subfamily E 
regulatory subunit 1
Acta2 Actin, alpha 2, smooth muscle, aorta Kdr Vascular endothelial growth factor receptor 2
Actn2 α-actinin (sarcomeric) Kit c-Kit
Alcam Activated leukocyte cell adhesion molecule mESC Mouse embryonic stem cell
Aldh1a2 Aldehyde dehydrogenase 1 family member a2 Mhc/MF20 Myosin, sarcomere
ATRA All-trans retinoic acid Myl2 Myosin light chain 2
atrRFP Atrial-specific (posterior) fluorescent reporter Myl7 Myosin light chain 2a
Axin2 Axin 2 Myh11 Myosin, heavy polypeptide 11
BX Bexarotene Nkx2.5 NK2 homeobox 5
Bmp Bone morphogenetic protein Nppa Natriuretic peptide A
Cdh2 Cadherin 2 Nppb Natriuretic peptide B
CHD Congenital heart disease Nr2f2 COUP transcription factor II
Cyp26a1 Cytochrome P450 retinoic acid-inactivating 1 Oct4 POU class 5 homeobox 1
Cyp26c1 Cytochrome P450 family 26 subfamily C member 1 Pecam1 Platelet/endothelial cell adhesion molecule 1
DMSO Dimethyl sulfoxide Pdgfra Platelet-derived growth factor receptor alpha
E10.5 Embryonic day 10.5 Pitx2 Paired-like homeodomain 2
EB Embryoid body RVD Repeat variable diresidue
ECG Electrocardiography Sln Sarcolipin
EST Embryonic stem cell test SMyHC3 Slow myosin heavy chain 3
Gata4 GATA binding protein 4 TALEN Tal effector nuclease
Gja5 Connexin-40 Tbx5 T-Box 5
hESC Human embryonic stem cell Tgf-β Transforming growth factor beta
Hey2 Hairy-related transcription factor 2 Thy1 Thymus cell antigen 1, theta
hIPSC Human-induced pluripotent stem cell Tnnt2 Cardiac muscle troponin T
Irx4 Iroquois homeobox 4 venGFP Ventricular-specific (anterior) fluorescent reporter
Isl1 Islet-1 Vim Vimentin
634 Archives of Toxicology (2020) 94:631–645
1 3
Generation of atrial‑specific transgene
The 840 bp sinoatrial-specific SMyHC3 promoter has been 
described previously (Xavier-Neto et al. 1999) and a con-
struct containing the sequence was obtained from Dr. Jose 
Xavier-Neto. A plasmid was generated in which this pro-
moter is used to drive the TdTomato fluorescent protein 
using infusion HD cloning (Clontech). In short, the 840 bp 
atria-specific sequence was amplified by PCR using 5′-CGG 
GCT GCA GGA ATT CCA CCA CAG TGG CCC CAT CC-3′ 
and 5′-ACC ATG GAT CCT GCA CAA TCC TGC TGC TGC 
CCC AC-3′. The TdTomato-pA gene was amplified by PCR 
using 5′-TGC AGG ATC CAT GGT GAG CA-3′ and 5′ TAA 
ACA AGT TCC GAG GCT GGG TAC CGG GCC CAA TG-3′, 
whereas the PGK-Neo cassette was amplified using 5′-CTC 
GGA ACT TGT TTA TTG CAGC-3′ and 5′-GCT TGA TAT 
CGA ATT AAA GGG AAC AAA AGC TGG AG-3′. Primer 
regions not in bold were added to facilitate HD fusion clon-
ing. The three fragments were cloned into EcoRI-digested 
pBluescript II KS( +) using the HD fusion cloning kit (Clon-
tech). The plasmid was sequenced to ensure fidelity.
Myl2 gene targeting in mESCs
The targeting vector and TALEN-encoding plasmids were 
introduced into E14 mESCs cultured in feeder-free condi-
tions using the Xfect transfection reagent (Clontech). Cor-
rectly targeted mESC clones were identified using 5′ junc-
tion PCR genotyping primers 5′-TTG AGA AGA GAC GCA 
GGG TG-3′ and 5′-GCT GAA CTT GTG GCC GTT TAC-3′, 
which amplify a PCR product encompassing the entire 5′ 
homology arm and part of the eGFP-bGH-PGK-Puro cas-
sette. Additionally, 3′ junction PCR primers 5′-TCC ATC 
AGA AGC TGG TCG AG-3′ and 5′-CCT CTA TGA TGG CCG 
CTG TC-3′ were used to identify positive clones. Clones 
positive from initial genotyping experiments were expanded 
and re-genotyped after six passages. A region flanking the 
TALEN targeting site was amplified from genomic DNA of 
expanded mutant cell lines using primers 5′-TTT CGC CTC 
GCA TGT TGT CTGGG-3′ and 5′-GGA TCG CTA CCC AGC 
GCC TT-3′ to identify heterozygous mutations. This band 
was sequenced, and a clone with a heterozygous knock-in 
 (Myl2eGFP/w) was used for further experiments.
Random integration of atrial‑specific transgene
Myl2eGFP/w mESCs were transfected with the linearized 
SMyHC3-TdTomato-PGK-Neo construct and clones with 
stable integration were manually isolated after 10 days of 
treatment with G418 (250 µg/mL). Stable integration in 
individual clones was confirmed by PCR genotyping using 
primers 5′-GGA GAT AAG GAG GCC AGA AAT AGC -3′ and 
5′-CTC ACG TAG AAC CCC CTT TGC-3′, which amplify a 
sequence within the SMyHC3-TdTomato cassette. Positive 
clones were tested for differentiation potential, and expres-
sion of the eGFP and TdTomato reporter genes was assessed 
by flow cytometry and microscopy after differentiation to 
cardiomyocytes.
Generation of reporter mESC‑derived embryos
Reporter mESCs were used to generate reporter embryos 
using eight-cell morula injection essentially as described 
(Poueymirou et  al. 2007). Embryos were dissected and 
imaged on a fluorescent stereomicroscope (Zeiss Axio 
Zoom.V16).
Cardiomyocyte differentiation in hanging drops 
with small molecules
For differentiation of reporter mESCs, cells were plated to 
V-bottomed 96-well plates at 500 cells/well in 20 µL embry-
oid body differentiation medium (DMEM, 20% fetal bovine 
serum, non-essential amino acids, glutamax, 2-mercaptoeth-
anol). Plates were inverted until day 2, when 200 µL medium 
was added. On day 5, EBs were then manually transferred 
to a 12-well plate coated with 0.1% gelatin at 6 EBs/well. 
Small-molecule compounds were diluted in DMSO and 
added to the cell culture medium at the indicated time points. 
All compounds were purchased from Sigma-Aldrich. D12 
spontaneous differentiation cultures were dissociated with 
TrypLE for 20 min on a shaker. TrypLE was inactivated 
with serum and cells were washed and resuspended in 1× 
PBS before analysis on a BD LSRFortessa flow cytometer. 
Wild-type EBs and Myl2-eGFP EBs were used as negative 
controls for gating. Analysis was performed using Flowjo 
(Flowjo LLC). For fluorescent microscopy of differentiated 
clones, cells were fixed in 4% PFA, permeabilized with 0.1% 
Triton-X and stained with anti-RFP antibody (Rockland) and 
Alexa Fluor secondary (Thermo) to increase the fluorescent 
signal. Reporter mouse pluripotent stem cells were charac-
terized by immunocytochemistry with an anti-Oct4 antibody 
(sc-8628). Characterization of sarcomeric protein expression 
in reporter cells was performed by immunocytochemistry for 
Mhc/MF20 (Developmental Studies Hybridoma Bank), and 
α-actinin (Sigma-Aldrich). Cells were imaged by epifluores-
cence (Zeiss Axioimager) or inverted fluorescence (Leica 
DMi8) microscopy.
Directed cardiomyocyte differentiation 
and high‑throughput detection
E14 wild-type,  Myl2eGFP/w, and  Myl2eGFP/w, SMyHC3-
TdTomato dual reporter mESCs were cultured in feeder-
free conditions on 0.1% gelatin in LIF-containing medium. 
Directed differentiation into cardiomyocytes was performed 
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as described with some modifications (Kattman et al. 2011). 
mESCs were allowed to form EBs in suspension culture and 
grown at 75,000 cells/mL in media composed of the follow-
ing: IMDM, Ham’s F12, BSA, Glutamax, B27 supplement, 
N2 supplement, monothioglycerol, and ascorbic acid. After 
2 days of suspension culture, EBs were dissociated with Try-
pLE and then re-aggregated for 40 h in media containing 
activin A (R&D Systems) and BMP4 (R&D systems). On 
day 4, EBs were again dissociated and replated at 125,000 
cells in 250 µL of StemPro, a serum-free medium (SP34, 
ThermoFisher Scientific #10639011) supplemented with 
VEGF (R&D systems), FGF10 (R&D systems), and FGFb 
(R&D systems) in ultra-low attachment 24-well plates. Day 
5 EBs were dissociated with the neonatal mouse dissocia-
tion kit (Milenyi) and plated to 384-well clear-bottomed 
black plates. Compounds were added to adherent cells at the 
indicated time points, and the differentiation efficiency was 
measured using a Pherastar fluorescent plate reader (BMG). 
Data consist of at least four biological replicates and four 
technical replicates within each experiment. For characteri-
zation of D6 cells by immunocytochemistry, cells were fixed 
in 4% PFA, permeabilized with 0.5% Triton-X and stained 
with anti-Isl antibody (Developmental Studies Hybridoma 
Bank) and Alexa Fluor secondary (Thermo).
Results
Gene expression analysis of the newly formed 
embryonic heart
We selected a genetic approach for the efficient detection 
of anterior–posterior marker expression during in vitro dif-
ferentiation. To assess specificity of markers to the anterior 
and posterior heart, we conducted a qPCR analysis of native, 
embryonic tissues to determine expression patterns of pub-
lished chamber-specific markers. We also analyzed markers 
of stromal cell differentiation, progenitor cells, and signaling 
pathways to identify relevant differences in the newly formed 
chambers and inform assay development. We selected E10.5 
hearts, as at this developmental time point the two atria and 
two ventricles have clearly formed. By choosing an early 
developmental stage, we sought to identify markers which 
would be suitable for in vitro differentiation, which produces 
immature cardiomyocytes. Known ventricle-specific genes 
such as Hey2, Irx4, Kcne1, and Myl2 were also upregulated 
in the ventricular compartment in our study (Fig. 1a). Impor-
tantly, Myl2 was the most upregulated ventricular gene (50-
fold higher than atria), suggesting its suitability for reporter 
cell generation (Fig. 1a). Published atrial markers Nr2f2, 
Myl7, Gja5, and Pitx2 were detected at increased levels in 
the atria (Fig. 1b), but also showed expression in the ven-
tricular compartment, confirming the lack of robust, native 
atrial markers during early embryogenesis in the mammalian 
system (Xavier-Neto et al. 1999). Sarcolipin was specifi-
cally expressed in the atrial compartment and absent in the 
ventricles (Fig. 1b), however, the presence of this marker 
in skeletal muscle makes it less suitable for differentiation 
analysis of mESCs (Babu et al. 2007). Importantly, the pan-
cardiac marker Tnnt2 showed no difference between atrial 
and ventricular compartments, suggesting equal composition 
of cardiomyocytes in the atria and ventricles (Fig. 1c).
In addition to known cardiomyocyte markers, we identi-
fied differences between the nascent compartments in stro-
mal cell type composition. Interestingly, fibroblast markers 
Cdh2 and Thy1 were upregulated in the ventricular compart-
ment, whereas smooth muscle marker Myh11 was upregu-
lated in the atrial compartment (Supplementary Fig. S1). 
Also, endothelial marker Pecam1 was upregulated within the 
ventricular compartment. These suggest the early ventricle 
has a more fibrotic/endothelial character, whereas the atria 
have more cells of a smooth muscle identity.
No difference in cardiac progenitor marker Nkx2-5 
was observed between the embryonic atria and ventricles 
(Fig. 1d). However, progenitor markers Kit and Kdr were 
upregulated in the ventricular compartment (Fig. 1d), indi-
cating the presence of endothelial progenitors in the devel-
oping ventricle (van Berlo et al. 2014). Additionally, the 
Isl1 transcription factor, a marker of the second heart field 
and later sinoatrial nodal cells, was upregulated within the 
atria (Fig. 1d).
Signaling pathway markers also displayed differences 
between atria and ventricles (Fig.  1e). To distinguish 
between canonical and non-canonical Wnt signaling, Axin2 
and Alcam, respectively, were used as target genes (Cizelsky 
et al. 2014; Yan et al. 2001). While canonical Wnt sign-
aling (Axin2) showed increased expression in atria, non-
canonical Wnt signaling (Alcam) was upregulated in the 
ventricles (Fig. 1e). Additionally, retinoic acid signaling 
genes Cyp26a1 and Aldh1a2 were upregulated in the atria 
compared to the ventricles (Fig. 1e). These confirm the pres-
ence of developmental signaling pathways across the cardiac 
chambers of the newly formed embryonic heart.
Generation of dual reporter mESC line with genome 
editing
TALEN-mediated genome editing was used to generate a 
mESC line from which anterior and posterior lineages could 
be efficiently analyzed after in vitro differentiation. To mark 
cells of the anterior (ventricular) lineage, Myl2 was selected 
for genomic modification, as Myl2 has been shown to be 
specific to ventricular segments of the heart during embry-
onic and adult stages (O’Brien et al. 1993).
TALEN-encoding plasmids were constructed to encode 
nucleases which induce a double-strand break in the second 
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exon of the mouse Myl2 locus. Additionally, a donor plas-
mid for in-frame integration of an eGFP-PGK-Puro cassette 
was generated (Fig. 2a). After transfection with TALEN-
encoding and donor plasmids, clones with an integration 
event were purified via puromycin selection, and correctly 
targeted mESC clones were identified by junction PCR (Sup-
plementary Fig. S2a). Selected clones with undifferentiated 
morphology were used for further experiments. Upon spon-
taneous differentiation in hanging drops, Myl2-eGFP expres-
sion was observed at D9–D10 of differentiation in areas with 
spontaneous beating. A single clone was selected for further 
targeting, hereafter referred to as  Myl2eGFP/w.
To our knowledge, no gene has been described which 
has expression only in mouse atrial cardiomyocytes during 
both embryonic and adult stages. Our qRT-PCR analysis of 
embryonic hearts also failed to identify endogenous markers 
of atrial cardiomyocytes not expressed in other mammalian 
cell types. We thus selected the atrial-specific enhancer/
proximal promoter of the quail slow myosin heavy chain 
(SMyHC3), previously shown to mark atrial cells dur-
ing all developmental stages and adulthood (Xavier-Neto 
et  al. 1999). A construct was assembled in which the 
SMyHC3 promoter drives the fluorescent protein TdTomato 
(SMyHC3-TdT-PGK-Neo) (Fig. 2a). After transfection and 
antibiotic selection with G418, stably transfected clones 
were identified by PCR (Supplementary Fig. S2b). A total 
of ten clones were differentiated in hanging drops, and one 
mESC clone was selected for further experiments, based 
on cardiomyocyte differentiation capacity and expression of 
both eGFP and TdTomato detectable by fluorescent micros-
copy and flow cytometry (Fig. 2b, c). For simplicity, these 
markers are hereafter referred to as venGFP (ventricular, 
anterior) and atrRFP (atrial, posterior). Immunocytochem-
istry of dual reporter mESCs indicates expression of the 
Oct-4 protein, a pluripotency marker, as well as character-
istic pluripotency morphology, further confirming that dual 
reporter mESCs represent cells in the pluripotent state (Sup-
plementary Fig. S3). Importantly, differentiated venGFP and 
atrRFP cardiomyocytes also expressed sarcomeric proteins 
myosin heavy chain (Mhc/MF20) and α-actinin, indicat-
ing the overlap of reporter expression with the contractile 
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Fig. 1  qRT-PCR profiling of the newly formed four-chambered 
mouse heart (E10.5). Published markers of a ventricular: Irx4, Hey2, 
Kcne1, Myl2 b atria: Nr2f2, Myl7, Gja5, Sln, Pitx2 c pan-cardiac: 
Tbx5, Tnnt2, Gata4, Nppb, Nppa d progenitor: Kit, Isl1, Kdr, Pdgfra, 
Nkx2.5 e Axin2, Alcam, Cyp26a1, Cyp26c1, Aldh1a2. Data are pre-
sented as mean + SEM (n = 3)
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imaging also revealed the presence of venGFP and atrRFP 
expression in spontaneously beating, differentiated cardio-
myocytes (Supplementary Fig. S5). These suggest the utility 
of reporter expression as an endpoint for assays which have 
previously used the detection of spontaneously beating cells.
Embryonic expression of venGFP and atrRFP 
in reporter mESC‑derived embryos
To confirm the correct expression of fluorescent reporters in 
the developing embryo, chimeric embryos were generated 
via laser-assisted morula injection of dual reporter mESCs. 
Embryos were dissected during early stages of cardiac devel-
opment from stages spanning the formation of the cardiac 
crescent to the fully looped heart. Reporter embryos are 
apparent in Fig. 3a–l. We observed robust venGFP expres-
sion at the cardiac crescent stage (E7.5) (Fig. 3a), pointing to 
reporter expression prior to the formation of the linear heart 
tube. Myl2 is known to be expressed when the lateral plate 
mesoderm forms into the linear tube and marks the primi-
tive ventricle (future left ventricle), but we have observed 
venGFP expression from the midline towards the distal ends 
of the cardiac crescent but not in the distal portion that will 
give rise to other fragments of the heart (Fig. 3a, b). atrRFP 
expression was not observed in this stage. In E8.25 embryos, 
we observed venGFP expression in the first beating chamber 
of the primitive ventricle (also reported by previous studies) 
and atrRFP expression in the forming venous pole region 
and the myocardial sinus horns of the embryonic heart 
(Fig. 3c, d). In E8.5 embryos, we observed venGFP at the 
primitive left ventricle, and atrRFP in the primitive, com-
mon atrium at the junction of the primitive ventricle and 
inflow region (Fig. 3e, f). In the rightward looping heart 
(E8.75), venGFP expression was observed in the future left 
ventricle (Fig. 3g, h). Interestingly, the future atrioventricu-
lar canal was marked by double positive cells, and atrRFP 
signal alone was visible in the sinus venosus region (Fig. 3g, 
h). In the E9.5 embryo, robust atrial and ventricular expres-
sion were observed (Fig. 3i–l). Collectively, we observed 
venGFP in the forming left ventricle, atrioventricular canal, 
and right ventricle/outflow tract. Moreover, we recorded 
atrRFP expression on the forming left and the right sides 
of the common atria at the junction of the dorsal aorta and 
atrioventricular canal. Our results mirror published reports 
of the expression of venGFP(Myl2-eGFP) and atrRFP 
(SMyHC3), confirming our fluorescent reporter expression 
is specific to atrial and ventricular regions during the earliest 
stages of cardiogenesis (O’Brien et al. 1993; Xavier-Neto 
et al. 1999). However, in contrast to previous studies, the use 
of a fluorescent reporter shows detail at the cellular level, 
in addition to a dynamic range of expression. Importantly, 
the onset and duration of fluorescent reporter expression in 
reporter cell-derived hearts coincides with spontaneous beat-
ing in differentiated cardiomyocytes of the embryonic heart. 
Furthermore, the ability of reporter mESCs to contribute to 
all embryonic structures and specifically express fluorescent 
reporters only in the heart is strong in vivo evidence for both 
pluripotency of reporter mESCs and specificity of reporter 
expression.
Gene expression dynamics during spontaneous 
differentiation of reporter mESCs
To gauge the suitability of in  vitro differentiation of 
reporter mESCs to cardiac chamber development, we 
conducted gene expression analyses of differentiat-
ing cells at three time points: D6 (before the onset of 
spontaneously beating cells), D9 (first appearance of 
small numbers of spontaneously beating cells), and D12 
(large numbers of beating clusters of cells) (Fig.  4a). 
Gene expression of ventricular, atrial, and pan-cardiac 



























Fig. 2  Generation of reporter mESC line. a Targeting strategy for 
generation of TALEN-mediated knock-in at the ventricle-specific 
Myl2 locus and random integration of atrial-specific SMyHC3-TdT 
into mESCs. b Fluorescent expression of ventricular and atrial report-
ers upon spontaneous differentiation to cardiomyocytes, ×10 mag-
nification. c Representative flow cytometry analysis of wild-type, 
Myl2eGFP/w, and dual reporter mESCs upon directed differentiation 
to cardiomyocytes and retinoid treatment
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D6–D12, in line with spontaneous beating observations 
(Fig. 4b–e). Similar expression dynamics were observed 
for smooth muscle (Myh11) and fibroblast (Thy1, Vim, 
Acta2) markers, suggesting that differentiation of these 
cell types occurs simultaneously with cardiomyocyte dif-
ferentiation (Supplementary Fig. S6). Multipotent, car-
diac progenitor markers (Kit, Isl1, Kdr, Pdgfra, Nkx2-5) 
were also observed, with highest expression levels at day 
9 (Fig. 4d). Early mesodermal marker (Brachyury) was 
more strongly expressed at D6 of differentiation, suggest-
ing that D6–D12 of differentiation covers both early and 
late mesodermal progenitor stages (Fig. 4d). Wnt targets 
(Axin2, Alcam) and retinoic acid components (Aldh1a2, 
Cyp26a1, Cyp26c1) were also expressed during the 
D6–D12 window (Fig. 4f). Interestingly, canonical Wnt 
Fig. 3  Anatomical localization of fluorescent reporter expression in 
chimeric embryos. a, b E7.5 embryo, venGFP (Myl2, green) expres-
sion in the cardiac crescent, bright field image showing cardiac 
crescent (cc) which will form the primitive ventricle (pv) of the lin-
ear heart tube, which is depicted by black lines. c, d E8.25 embryo, 
venGFP expression in the primitive ventricle, atrRFP (red) in the 
inflow region of the linear heart tube, bright field image showing 
sinus horns (sh), inflow region (inf) of the linear heart tube which 
together makes the venous pole of the heart and primitive ventricle. 
The horizontal line depicts the axis of the embryo prior to looping. e, 
f E8.5 embryo, venGFP expression in the primitive ventricle/future 
left ventricle, atrRFP expression in the inflow region of the develop-
ing heart and developing primitive atrium (pa) observed by a small 
ballooning at the junction of the horizontal line which is angled by 
the starting of looping. g, h E8.75 embryo, the horizontal line shows 
advancement of looping observed by the elliptic right side of the 
primitive ventricle and the left side of the primitive left ventricle 
which connects to the primitive atrium. i, j E9.5 embryo, right side, 
advancement of the looping outflow tract (oft)/ right ventricle (rv) 
showing venGFP expression and the left part of the common atria 
(ra) showing atrRFP expression. k, l E9.5 embryo, right side, venGFP 
expression in left ventricle (lv), atrRFP expression in the left part of 
the common atria (la) and in the connection of the left ventricle, left 
atria. Red–green regions (orange) in the atrioventricular canal (AVC) 
regions are visible (color figure online)
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(Axin2) and non-canonical Wnt (Alcam) displayed inverse 
temporal expression, in line with previous observations 
that non-canonical Wnt replaces canonical Wnt during 
cardiomyocyte differentiation (Mazzotta et  al. 2016). 
Retinoid degrading enzymes Cyp26a1 and Cyp26c1 also 
showed inverse temporal expression, as Cyp26c1 replaced 
Cyp26a1 during D6–D12 differentiation (Fig. 4f). To our 
knowledge, this has not been described previously, and has 
potential implications for teratogenic effects of retinoid 
treatment. Endogenous retinoic acid signaling (Aldh1a2) 
was nearly absent at D6 of differentiation, and increased 
at D9 and D12 time points. As retinoic acid signaling is 
thought to be a principal component of anterior–posterior 
patterning of the heart (Xavier-Neto et al. 1999), this sug-
gests that in the absence of exogenous retinoid treatment, 
in vitro retinoic acid patterning of multipotent cardiac 
progenitor cells occurs during D6–D12 spontaneous dif-
ferentiation of reporter mESCs. Collectively, these results 
show that embryonic cardiac chamber differentiation genes 
are expressed during D6–D12 spontaneous differentiation 
of mESCs, suggesting the suitability of the in vitro model 
for compound testing.
Stage‑specific effects of retinoids on expression 
of anterior–posterior reporters during spontaneous 
differentiation of reporter mESCs
To assess the functionality of a dual reporter differentia-
tion assay, we tested commercially available retinoids with 
known teratogenic properties for effects on fluorescent 
reporter expression (Table 2). Initial experiments showed 
that D2–D10 addition of high concentrations of all-trans 
retinoic acid (10 µM) completely eliminates the cardiac lin-
eage and expression of both venGFP and atrRFP. As our aim 
was to detect more subtle defects in patterning, we selected 
shorter time windows and smaller doses for our experiments 
based on the appearance of spontaneous beating, venGFP/
atrRFP expression, and temporal gene expression analysis. 
Time points for compound addition were selected shortly 
before (D6–D9) and after the appearance of beating cardio-
myocytes (D9–D12). As the linear heart tube of E8 embryos 
ba c
ed f
Fig. 4  qRT-PCR profiling of spontaneous differentiation in reporter 
mESCs. a Differentiation schematic for sampling at D6, D9, and 
D12 of differentiation for detection of markers of b atria: Nr2f2, 
Myl7, Gja5, Sln, Pitx2, TdTomato c ventricles: Irx4, Hey2, Kcne1, 
Myl2 d progenitor cells: Kit, Isl1, Kdr, Pdgfra, Nkx2.5, Brachyury e 
pan-cardiac: Tbx5, Tnnt2, Gata4, Nppb, Nppa f signaling pathways: 
Axin2, Alcam, Cyp26a1, Cyp26c1, Aldh1a2. Data are presented as 
mean ± SEM for each time point (n = 3)
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beat robustly, we estimate these earliest myocytes roughly 
approximate E8–E10 hearts.
Results of differentiation experiments are shown in 
Fig. 5. Regardless of compound treatment window, cultures 
were measured on D12 of differentiation for %venGFP 
and %atrRFP cells, mean fluorescent intensity (MFI) of 
venGFP and atrRFP, and atrRFP/venGFP ratio. Both ante-
rior and posterior cell populations were strikingly sensitive 
to retinoid treatment during early time windows. A sig-
nificant decrease in the %venGFP cells was observed for 
D6–D9 treatment with ATRA (1 µM and 10 µM) and 9CRA 
(0.1 µM, 1 µM, 10 µM), but not by BX (Fig. 5a). A decrease 
in venGFP-MFI was observed during D6–D9 treatment with 
ATRA (1 µM, 10 µM), 9CRA (1 µM, 10 µM), and BX (1 µM, 
10 µM) (Fig. 5b). Similar to D6–D9 treatment, a decrease 
in %venGFP + cells was induced by D9–D12 treatment with 
ATRA (1 µM, 10 µM) and 9CRA (1 µM, 10 µM), but not 
by BX (Fig. 5a). The venGFP-MFI showed an increase in 
venGFP levels with high levels of 9CRA (10 µM) and BX 
(10 µM) during D9–D12 treatment. These results clearly 
show the stage-specific effects of retinoids on fluorescent 
reporter expression.
Expression of the atrRFP reporter was also affected by 
retinoids (Fig. 5c, d). We observed a statistically significant 
decrease in %atrRFP cells upon D6–D9 treatment with 
ATRA (1 µM, 10 µM) and 9CRA (1 µM), but no statis-
tically significant effects from BX treatment. atrRFP-MFI 
decreased upon D6–D9 treatment with ATRA (0.1 µM, 
1 µM, 10 µM) and 9CRA (1 µM, 10 µM), but was unaf-
fected by BX treatment. A decrease in %atrRFP cells was 
observed in D9–D12 treatment with ATRA (1 µM), while 
a decrease in atrRFP-MFI during D9–D12 treatment was 
observed for ATRA (0.1 µM, 1 µM, 10 µM) and 9CRA 
(10 µM). Non-statistically significant increases in %atrRFP+ 
cells were observed for early (D6–D9) 9CRA (0.1 µM) and 
BX treatment (0.1 µM, 1 µM), as well as late (D9–D12) 
9CRA (0.1 µM) and BX treatment (0.1 µM).
The effects of atrialization of the total cardiac pro-
genitor pool by retinoids were explored via quantifica-
tion of atrial/ventricular ratio and atrRFP/venGFP-MFI 
ratio (Fig.  5e, f). Increases in atrial/ventricular ratio 
were observed for nearly all retinoids at early time points 
D6–D9, though only ATRA (0.1 µM) was statistically 
significant. This suggests that the atrializing potential of 
ATRA exists prior to the onset of spontaneous beating, 
as observed previously (Lee et al. 2017). atrRFP-MFI/
venGFP-MFI levels were increased at early time points 
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D6–D9 by ATRA (10 µM) and BX (10 µM), but decreased 
at later time points by ATRA (0.1 µM, 1 µM, 10 µM) 
and 9CRA (10 µM). Collectively, these results indicate 
increased severity of cardiovascular developmental toxic-
ity from dual RAR/RXR agonists (ATRA, 9CRA) than 
RXR agonists (BX). These results also confirm the com-
plex time and spatial characteristics of retinoic acid signal-
ing during cardiogenesis, and indicate this can be partially 
recapitulated in vitro with reporter cell lines using a spon-
taneous differentiation model. Interestingly, these results 
mirror the time-dependent effects of retinoid acid signal-
ing in the zebrafish model (Keegan et al. 2005).
Chemical modulation of retinoic acid, Wnt, 
and TGFβ pathways in high‑throughput ventricular 
differentiation
To assess the feasibility of a high-throughput differentiation 
assay (384-well format), we developed a protocol for gen-
eration of a large number of cardiac progenitors in chemi-
cally defined conditions. We modified a widely used proto-
col requiring serial dissociation of EBs and treatment with 
BMP4/activin A to generate large enough number of multi-
potent cardiac progenitors for efficient toxicological screen-
ing (Kattman et al. 2011). The most significant modification 

































































































































































































































































































































































































































































































































































































































































Fig. 5  Effects of retinoids on reporter expression during spon-
taneous differentiation of reporter mESCs. D12 measure-
ments of a %venGFP + cells b venGFP-mean fluorescent inten-
sity c %atrRFP + cells d atrRFP-mean fluorescent intensity e 
%atrRFP/%venGFP f atrRFP-MFI/venGFP-MFI. Fluorescence 
activity was normalized to DMSO and is presented as mean + SEM 
(n = 5). **P < 0.01, *P < 0.05 (Wilcoxon test vs DMSO control)
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ultra-low attachment plates instead of to adherent conditions, 
allowing the generation of a large number of D5 multipotent 
cardiac progenitors (~ 20 million). These were plated to 384-
well plates for total fluorescence analysis on D10 of differ-
entiation. Total fluorescence of venGFP could be measured, 
but not atrRFP, likely reflecting the difference in strength of 
these two promoters, the preferential induction of ventricular 
cardiomyocytes via the protocol, and the reduced sensitiv-
ity of the plate reader format compared to flow cytometry. 
Indeed, flow cytometric analysis from cells differentiated via 
this protocol generated a strong preference for cells of the 
ventricular lineage (Supplementary Fig. S7). This is also in 
line with a recent study which found the necessity of titrat-
ing BMP4/activin A-induced mesodermal specification to 
generate cells capable of differentiation to the atrial lineage 
(Lee et al. 2017).
Spontaneous beating occurs at D7 in this assay and was 
used as a reference point for compound addition points. 
Importantly, venGFP cells beat robustly in cell sheets in the 
384-well format, and the abundance of beating correlates 
qualitatively with the amount of venGFP cells. In conditions 
with highly efficient differentiation, the cells beat synchro-
nously in a unified cell sheet. Compounds modulating reti-
noic acid (ATRA), TGF-β (SB431542), and Wnt (XAV939) 
signaling pathways were tested in this assay system during 
two windows, one in which compounds are added before 
the onset of beating (D6–D8), and one in which compounds 
are added after the onset of beating (D7–D9) (Fig. 6a). 
D6 cells also express the multipotent cardiac progenitor 
marker Isl1, confirming their undifferentiated, progenitor 
state (Fig. 6b). Early addition (D6–D8) of ATRA caused 
a decrease in venGFP fluorescence, whereas late addition 
resulted in an increase in venGFP fluorescence (D7–D9) 
(Fig. 6c, d). This suggests biphasic effects of retinoic acid 
signaling on late progenitor specification to ventricular 
cardiomyocytes. Inhibition of both Tgf-β (SB431542) and 
canonical Wnt (XAV939) increased venGFP fluorescence 
when added prior to spontaneous beating, but showed no 
statistically significant effects when added after the onset of 
beating (Fig. 6c, d). This also suggests divergent roles for 
these pathways in multipotent cardiac progenitors and dif-
ferentiated cardiomyocytes. Overall, these results indicate 
the potential for detection of stage-specific differentiation 
modulation of chamber-specific cardiomyocytes in a high-
throughput system. Additionally, they further confirm that 
the in vitro commitment of cells to anterior–posterior line-
ages largely occurs before the onset of spontaneous beating.
Discussion
To facilitate the detection of teratogens which are deleteri-
ous to fetal health, we developed an in vitro model based on 














































































































Fig. 6.  384-well plate screening in reporter mESCs in serum-free 
conditions. a Schematic of serum-free differentiation system for high-
throughput screening. b Immunocytochemistry of cardiac progenitor 
marker Isl1 on D6 of the differentiation protocol, ×40 magnifica-
tion. c Representative wells of compound treatment showing effects 
of compounds on Myl2 promoter activation upon D6-D8 treatment, 
×5 magnification. d D10 total fluorescence measurements of venGFP 
upon treatment either before (D6–D8) or after (D7–D9) the onset of 
beating. Fluorescence activity was normalized to DMSO and is pre-
sented as mean + SEM (n = 4). **P < 0.01, *P < 0.05 (Wilcoxon test 
vs DMSO control)
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qRT-PCR analysis of early four-chambered hearts, we have 
identified suitable markers for genome modification and 
gained insight into the spatially distinct cell composition of 
the embryonic heart. TALEN-mediated genome editing was 
used to generate a dual reporter mESC line for more effi-
cient detection of differentiated lineages, and expression of 
reporter alleles was observed in chimeric embryos and dur-
ing both spontaneous and directed differentiation of mESCs 
at the onset of spontaneous beating. To our knowledge, this 
is the first reporter cell line in the mammalian system includ-
ing markers for both anterior and posterior cardiac lineages 
simultaneously. Furthermore, the reporter system described 
here presents an alternative readout to the counting of beat-
ing clusters currently used as part of the EST, and allows for 
adaptation to high-throughput screening for developmental 
toxicity.
Using our reporter system, we delineated the windows of 
action of a panel of retinoids, demonstrating their effects on 
the induction of expression of anterior–posterior markers 
in vitro. Retinoic acid is a potent teratogen, and in humans 
principally causes malformation of the heart, nervous 
system, and craniofacial tissues (Lammer et al. 1985). In 
zebrafish and mouse models, retinoic acid signaling has been 
implicated in both limiting the number of cardiac progeni-
tors in the cardiac crescent and patterning progenitors into 
anterior–posterior compartments (Keegan et al. 2005; Ryck-
ebusch et al. 2008; Xavier-Neto et al. 1999). Our in vitro 
results also reflect biphasic retinoid acid signaling, as we 
observed both inhibition and promotion of anterior–poste-
rior lineages which were dependent upon the time of treat-
ment (D6–D9 vs D9–12). These results suggest lineage 
commitment of cells to anterior–posterior fates precedes the 
onset of beating, and this coincides with replacement of reti-
noic acid-degrading enzyme Cyp26a1 with Cyp26c1. To our 
knowledge, this has not been described previously, and has 
potential implications for teratogenic effects of retinoid treat-
ment. We also observed that low concentrations of retinoic 
acid administered before the onset of beating preferentially 
inhibited the ventricular lineage but did not affect the atrial 
lineage, mirroring the atrialization seen in zebrafish models 
(Keegan et al. 2005).
For large-scale toxicological screening, detection of 
reporter alleles with a high-throughput plate reader would 
be desirable. In the present study, we adapted a directed dif-
ferentiation protocol to a high-throughput, 384-well plate 
format. We utilized a directed differentiation protocol in 
chemically defined medium to generate cardiac progeni-
tor populations suitable for fluorescent protein detection. 
This screening system was capable of detecting expression 
from the venGFP (Myl2), but not atrRFP (SMyHC3) pro-
moters, and this can be partially explained by differences in 
the strength of these promoters in the mouse system. Re-
engineering of reporter alleles to express the more easily 
detectable luciferase instead of fluorescent proteins might 
resolve this issue. Additionally, the directed differentiation 
system we employed mostly produces cardiomyocytes of the 
ventricular lineage (Lee et al. 2017). Further optimization 
of our directed differentiation protocol to Cyp26a1+ and 
Cyp26a1− mesoderm would likely be necessary to achieve 
detection of the SMyHC3 promoter in a high-throughput 
format (Lee et al. 2017). However, the screening system we 
employed was successful in detecting the effects of Wnt, 
TGF-β, and retinoid signaling pathway alteration on differ-
entiation to the ventricular lineage.
Though developmental toxicity was the aim of this study, 
aberrant expression of atrial/ventricular identity genes might 
also predict physiological defects arising from developmen-
tal exposure to teratogens. Ventricular upregulation of the 
SMyHC3 transgene during embryogenesis was shown to 
precede adult-onset pathological hypertrophy upon deletion 
of the transcription factor Irx4 in the murine model (Bruneau 
et al. 2001). Perturbed Wnt signaling during development 
can also lead to chamber-specific arrhythmias in adulthood 
due to underlying defects in chamber-specific gene expres-
sion (Li et al. 2018). These effects are overlooked by the 
existing EST, and cannot be feasibly routinely tested in vivo, 
as pups from pregnant mothers in embryonic toxicity studies 
would necessarily be brought to term and subjected to ECG 
and telemetry recordings. Our assays, which use chamber-
specific gene expression as a readout of differentiation, could 
potentially uncover subtle developmental toxicity which 
results in adult disease due to altered chamber-specific gene 
expression.
Teratogenic activities have not been determined in 
humans/human cell models for more than 90% of drugs, 
and rodent studies may not always be predictive (van Gelder 
et al. 2010). Though the present study was conducted in 
mESCs, in line with previous iterations of the EST, a 
clear goal would be to develop a reliable system in human 
embryonic stem cells (hESCs)/human-induced pluripotent 
stem cells (hIPSCs). One limitation is that there is no fea-
sible method of validating transgene expression in human 
embryos, in contrast to transgenic mouse methods in which 
chimeric embryos show a clear overlap of anatomical expres-
sion, as in the current study. Other barriers to establishment 
of hPSC methods include the ethical issues surrounding 
hESCs, and the oncogenic mutations known to exist in most 
hIPSC lines (Merkle et al. 2017). mESC models based on 
transgenic lines thus still hold advantages in terms of cost, 
validation, and the existence of well-characterized reporter 
alleles (Kugler et al. 2016a, b).
In the present study, only a small set of compounds in a 
small number of time windows were tested. Future efforts 
must focus on testing a larger set of well-characterized 
reference compounds for their effects on anterior–posterior 
patterning in shorter time windows. As some non-familial 
644 Archives of Toxicology (2020) 94:631–645
1 3
CHD cases could be due to non-medical exposure to envi-
ronmental pollutants and industrial byproducts, these 
could also be tested for safety windows in low-cost, high-
throughput differentiation assays (Ou et al. 2017). Addi-
tionally, the same time windows presented here could be 
tested in other reporter lines which have been developed 
for toxicological assessment, such as a recently described 
Wnt/Β-catenin reporter (Kugler et al. 2016a, b).
As the heart is the first organ to form, and its devel-
opment includes most key developmental signaling path-
ways, interruption of cardiac differentiation in vitro might 
not only reflect interference with in vivo cardiogenesis, 
but could also be predictive of a general disruption of 
in vivo organogenesis. Indeed, defects in the patterning 
of the heart might be predictive of defects in pattern-
ing of limbs and craniofacial tissue, as significant over-
lap exists in those developmental programs (Diogo et al. 
2015). Thus, by developing adequately validated, step-
wise cardiac differentiation assays, the need for conduct-
ing differentiation assays to other lineages (endodermal, 
ectodermal) could be eliminated. We also envision such 
stage-specific analyses of different reporter alleles in the 
context of cardiac differentiation of mESCs will allow the 
study of previously misunderstood mechanisms of devel-
opmental toxicity. Mechanistic information gained from 
high-throughput assays could also aid in the identification 
of off-target effects early in the drug development process 
and an overall reduction in the congenital disease burden.
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